Chronic Kidney Disease: The Silent Aging Epidemic That Kills 1 in 7 Adults

Your kidneys do not have symptoms until they have catastrophes.

1 in 7 US adults has chronic kidney disease. 9 out of 10 of them do not know it.

That is not a headline designed to scare you. It is the consistent finding from the National Health and Nutrition Examination Survey (NHANES), the largest ongoing population health dataset in the country, replicated across two decades of data collection (Murphy et al., Ann Intern Med 2016, PMID 27479614; CDC CKD Surveillance System, 2023). Roughly 37 million American adults have measurable kidney damage. Only about 10% of them can tell you that.

Chronic kidney disease (CKD) is the quietest high-mortality condition in medicine. It has no hallmark symptom in its early and middle stages. It produces no pain, no visible swelling, no dramatic event that sends you to an ER. It shows up in two cheap lab numbers that most primary care visits do not flag until things are already serious. And by the time your serum creatinine drifts above the "normal" line on a standard blood panel, you may have already lost more than half of your kidney function.

The Global Burden of Disease 2017 Kidney Disease Collaborators estimated that CKD caused 1.2 million deaths worldwide in 2017 and is projected to become the fifth leading cause of years of life lost by 2040 (Bikbov et al., Lancet 2020, PMID 32061315). That is a disease trajectory on par with Alzheimer's and outpacing most cancers. And unlike Alzheimer's, CKD has cheap, validated screening and — as of the last five years — actual disease-modifying drugs.

This article is a map. What CKD actually is. Why it hides. The two tests every adult over 40 should get. The four risk factors that drive 80% of cases. The protein myth. The newer therapies that finally shifted outcomes after two decades of stagnation. And why the lifters in your gym keep getting flagged for "kidney damage" they do not have.

TL;DR — Key Takeaways

• ~14% of US adults have CKD, and ~90% are unaware (NHANES, PMID 27479614)
• CKD is defined by two numbers: eGFR (filtering rate) and UACR (protein leak) — both are needed; one without the other misses cases
• Four drivers cause most CKD: diabetes (~38%), hypertension (~26%), age, and chronic NSAID use — smoking and obesity amplify both
• SGLT2 inhibitors (DAPA-CKD PMID 32970396, EMPA-KIDNEY PMID 36331190) cut kidney disease progression by 28-39% in both diabetic and non-diabetic CKD
• Finerenone (FIDELIO-DKD PMID 33031652) and semaglutide (FLOW PMID 38785210) further reduce progression in diabetic CKD
• Intensive BP control (SBP <120, SPRINT PMID 26551272) reduces cardiovascular and all-cause mortality but modestly accelerates short-term creatinine rise
• High protein intake does not damage healthy kidneys (Devries meta-analysis, PMID 30383278). Protein restriction is only indicated after CKD diagnosis
• Creatine supplementation raises serum creatinine by 10-25% without damaging nephrons — a measurement artifact, not kidney injury. Lifters should request cystatin C-based eGFR

What Chronic Kidney Disease Actually Is

Your kidneys are two fist-sized filters containing roughly one million nephrons each — the functional units that clean your blood. Each nephron has a glomerulus (a ball of capillaries that filters fluid out of the bloodstream) and a tubule (which reabsorbs what you need and excretes what you don't). Collectively, healthy kidneys filter about 180 liters of fluid per day, return 99% of it to circulation, and produce roughly 1.5 liters of urine.

CKD is defined by the international KDIGO (Kidney Disease: Improving Global Outcomes) guideline as abnormalities of kidney structure or function present for more than 3 months, with implications for health. In practice, that means either:

1. eGFR below 60 mL/min/1.73m² (estimated glomerular filtration rate — how much blood your kidneys filter per minute, normalized to body surface area), or
2. Markers of kidney damage (most commonly, albumin in the urine above 30 mg/g creatinine), or
3. Both.

CKD is then staged by eGFR (G1 through G5) and albuminuria (A1 through A3):

The nuance that matters: a person with eGFR 95 and UACR 500 has CKD. A person with eGFR 55 and UACR 10 has CKD. A person with eGFR 62 and UACR 25 has neither — but is on a trajectory you should watch.

Why CKD Is Silent — The Reserve Capacity Problem

The kidney is the evolutionary overachiever of your organs. You were born with roughly two million nephrons. You can donate one kidney and live a normal life. You can lose 50% of total function and feel nothing. You can lose 70% of total function and still pass a routine physical if nobody orders the right tests.

This is because glomerular filtration has enormous functional reserve. When nephrons are lost, surviving nephrons compensate by hyperfiltering — pushing more fluid through each remaining unit. That compensation keeps your eGFR looking deceptively normal for years while underlying nephrons are failing. It also accelerates the destruction of the nephrons that are left. Hyperfiltration is not a workaround; it is a slow-motion suicide pact among your remaining kidney tissue.

By the time serum creatinine rises above the "normal" lab range (typically ~1.2 mg/dL for men, ~1.0 for women), you may already have lost 60% of your baseline kidney function. Creatinine is a late signal, not an early one. It is also distorted by muscle mass: a 240-pound powerlifter and a 110-pound grandmother can have identical serum creatinine and wildly different actual GFRs.

This is why the modern standard is not "check creatinine." It is the CKD-EPI equation, which turns creatinine into an eGFR estimate while accounting for age and sex (Levey et al., Ann Intern Med 2009, PMID 19414839). In 2021, CKD-EPI was updated to remove the race coefficient and to optionally incorporate cystatin C, a second kidney marker that is independent of muscle mass (Inker et al., NEJM 2021, PMID 34554658). The race-free equation is now standard in most US labs.

And critically: eGFR alone still misses a huge fraction of early CKD. The CKD Prognosis Consortium meta-analysis of more than 1.2 million participants showed that albuminuria predicts mortality and kidney failure independently of eGFR — a person with eGFR 80 and heavy albuminuria has a worse prognosis than a person with eGFR 55 and no protein leak (Matsushita et al., Lancet 2010, PMID 20483451).

You need both numbers. One without the other misses cases.

The Two Tests Every Adult Over 40 Should Get

There are only two.

1. eGFR (from a basic metabolic panel)

Already included in most routine blood work. Your doctor orders a BMP or CMP — the lab reports serum creatinine and, increasingly, an automatically calculated eGFR using the 2021 race-free CKD-EPI equation. Cost: typically bundled into an annual physical. If you want the most accurate number, ask for cystatin C-based eGFR in addition to creatinine-based — especially if you are muscular, on a high-protein diet, or taking creatine.

2. UACR — Urine Albumin-to-Creatinine Ratio

A single spot urine sample, not a 24-hour collection. Cost: ~$10-30. This is the test that catches early damage before eGFR moves. In diabetes, microalbuminuria (UACR 30-300) typically precedes eGFR decline by 5-10 years and is the single best early warning sign of diabetic nephropathy.

UACR is underutilized. Most primary care visits do not order it unless the patient is already diabetic. If you are over 40, especially if you have any of the risk factors below, ask for it explicitly. Annual screening if normal, more often if abnormal.

Two numbers. eGFR and UACR. That is the entire entry-level kidney dashboard.

The Four Biggest Drivers

1. Diabetes (~38% of CKD cases in the US)

Chronic hyperglycemia damages the glomerular basement membrane, promotes hyperfiltration, and drives mesangial matrix expansion. Diabetic nephropathy is the single leading cause of end-stage kidney disease in the US. Tight glycemic control (HbA1c typically <7%) slows progression; SGLT2 inhibitors and GLP-1 agonists slow it further.

2. Hypertension (~26% of CKD cases)

High systemic pressure transmits into the glomerulus, damaging the filtering barrier and accelerating sclerosis. The SPRINT trial (SPRINT Research Group, NEJM 2015, PMID 26551272) randomized 9,361 high-risk adults to intensive BP control (target SBP <120) versus standard (<140). Intensive control reduced cardiovascular events by 25% and all-cause mortality by 27%. The kidney subgroup analysis (Cheung et al., JASN 2017, PMID 28592423) showed a short-term rise in creatinine with intensive control — which initially alarmed clinicians — but did not translate into worse long-term kidney outcomes and was outweighed by cardiovascular mortality reduction.

The pragmatic target for most adults: SBP <130, ideally closer to 120 if tolerated.

3. Age

GFR declines roughly 0.75-1 mL/min per year after age 30-40. A healthy 80-year-old may have an eGFR of 65-75 without any pathology. The question is whether the decline is accelerating beyond normal aging — which is where UACR, blood pressure, and glycemic status reveal whether a low eGFR is benign aging or pathology.

4. NSAIDs (ibuprofen, naproxen, diclofenac)

Chronic or high-dose non-steroidal anti-inflammatory drug use constricts the afferent arteriole (the vessel feeding each glomerulus), drops glomerular perfusion, and — in susceptible people — causes acute kidney injury that may not fully resolve. A systematic review by Nderitu et al. (Fam Pract 2013, PMID 23825187) found meaningful associations between long-term NSAID use and CKD progression, especially in older adults and those with existing risk factors.

Occasional use for acute pain is fine. Daily ibuprofen for months is not. If you are taking NSAIDs more than twice a week on an ongoing basis, that is a conversation with your doctor.

Amplifiers: Smoking (accelerates vascular damage and doubles CKD progression risk), obesity (drives hyperfiltration and diabetes), and family history (APOL1 variants in people of African ancestry dramatically increase CKD risk).

The Protein Myth vs. Reality

For decades, a reflexive belief in nutrition circles held that "high protein damages your kidneys." It is one of the most persistent myths in popular health.

The reality is more precise. In healthy kidneys, protein intake up to and beyond the RDA does not cause damage. A 2018 systematic review and meta-analysis of 28 randomized trials in healthy adults (Devries et al., J Nutr 2018, PMID 30383278) found no difference in kidney function between higher-protein diets (often >1.5 g/kg/day) and lower-protein diets. Short-term eGFR rises on high-protein diets reflect physiological hyperfiltration, not injury — similar to how your heart rate rises during exercise without damaging your heart.

In diseased kidneys, protein restriction has a modest benefit. The landmark MDRD trial (Klahr et al., NEJM 1994, PMID 8114857) showed that a very-low-protein diet slightly slowed GFR decline in advanced CKD, though the effect was smaller than many clinicians had hoped. Modern KDIGO guidelines recommend protein intake of ~0.8 g/kg/day in non-dialysis CKD stages 3-5.

The practical translation: if your eGFR and UACR are normal, eat protein. Aim for 1.2-1.6 g/kg/day if you are training, aging, or trying to preserve lean mass. If you have been diagnosed with CKD stage 3 or worse, work with a renal dietitian.

Newer Therapies That Actually Changed Outcomes

From the 1990s through the early 2010s, the only kidney-protective drugs were ACE inhibitors and angiotensin receptor blockers (ARBs). Then, in the last five years, three drug classes rewrote the CKD treatment playbook.

SGLT2 Inhibitors

Originally developed as glucose-lowering drugs for type 2 diabetes, sodium-glucose co-transporter 2 inhibitors turned out to have kidney and cardiovascular benefits that had nothing to do with their glucose effect.

• DAPA-CKD (Heerspink et al., NEJM 2020, PMID 32970396): 4,304 patients with CKD (with or without diabetes) randomized to dapagliflozin vs. placebo. The trial was stopped early for efficacy. Dapagliflozin cut the composite kidney outcome (≥50% eGFR decline, end-stage disease, kidney or CV death) by 39%.
• EMPA-KIDNEY (EMPA-KIDNEY Collaborative Group, NEJM 2023, PMID 36331190): 6,609 CKD patients (broader inclusion than DAPA-CKD) randomized to empagliflozin vs. placebo. Primary outcome — kidney disease progression or cardiovascular death — reduced by 28%.
• CREDENCE (Perkovic et al., NEJM 2019, PMID 30990260): canagliflozin in diabetic CKD, 30% reduction in composite renal endpoint.

The effect is independent of blood sugar. SGLT2 inhibitors reduce intraglomerular pressure, dial down hyperfiltration, lower albuminuria, and appear to protect nephrons through multiple mechanisms. They are now first-line in CKD with or without diabetes in current KDIGO guidance.

GLP-1 Agonists

FLOW (Perkovic et al., NEJM 2024, PMID 38785210): 3,533 patients with type 2 diabetes and CKD randomized to semaglutide vs. placebo. The primary kidney composite outcome was reduced by 24%. GLP-1 receptor agonists, best known for glucose control and weight loss, now have a clear kidney-protective signal in diabetic CKD.

Finerenone

A non-steroidal mineralocorticoid receptor antagonist — a structurally different cousin of spironolactone with less hormonal side-effect burden and a specific anti-fibrotic, anti-inflammatory profile in the kidney.

• FIDELIO-DKD (Bakris et al., NEJM 2020, PMID 33031652): 5,734 patients with diabetic CKD, 18% reduction in the primary kidney outcome.
• FIGARO-DKD (Pitt et al., NEJM 2021, PMID 34449181): cardiovascular composite reduced by 13%.

Finerenone layers on top of ACE/ARB and SGLT2 inhibitor therapy and is now part of the standard diabetic CKD regimen.

None of these drugs reverse CKD. What they do is slow the slope of decline, buying years of kidney function and sharply reducing the risk of dialysis or transplant. For someone diagnosed at eGFR 45, the difference between these drugs and no drugs may literally be whether they ever reach end-stage disease.

Lifestyle Interventions That Preserve Function

Before drugs, before nephrology referral, the foundation:

• Blood pressure: Target <130/80 in most adults; tighter if tolerated. Home BP monitoring is more accurate than single office readings.
• Glucose control: HbA1c <7% in most diabetics, individualized for older adults and those with hypoglycemia risk.
• Avoid chronic NSAIDs: Acetaminophen is generally safer for ongoing pain (within label dose).
• Hydration: Plain water. Chronic dehydration concentrates toxins and stresses filtration. No specific liter count beats "urine pale yellow."
• No smoking: Smoking approximately doubles the rate of CKD progression.
• Weight management: Every BMI point below obese reduces hyperfiltration load.
• Moderate alcohol: Heavy alcohol drives hypertension, which drives CKD. Light intake is neutral in most data.
• Sleep apnea: Untreated OSA drives resistant hypertension, which drives CKD. Get evaluated if you snore heavily or have daytime sleepiness.

Supplements are mostly irrelevant here, and the longevity supplement space frequently overpromises benefits to kidney function that are not supported by outcome trials. The evidence-based lever is lifestyle plus the three drug classes above for those with diagnosed disease.

Creatine and eGFR — Why Lifters Get False Flags

If you lift weights, take creatine, or eat a high-protein diet, you may have had this experience: you get a routine physical, the lab panel comes back, and your doctor tells you your creatinine is "slightly elevated — we should keep an eye on your kidneys."

In most cases, your kidneys are fine.

Creatinine is a breakdown product of creatine in muscle. If you have more muscle mass, or if you are supplementing creatine, you produce more creatinine per day. Your kidneys clear it at the same rate — so serum creatinine rises by roughly 10-25% without any change in actual filtration (Kreider et al., J Int Soc Sports Nutr 2017, PMID 28615996; Poortmans & Francaux, Med Sci Sports Exerc 1999, PMID 10449017). The CKD-EPI equation, which assumes typical muscle mass, then spits out an eGFR that looks lower than it really is.

The fix: ask for cystatin C-based eGFR. Cystatin C is a small protein produced by every nucleated cell in the body at a relatively constant rate. It is filtered by the glomerulus and not significantly affected by muscle mass, creatine supplementation, or diet. The 2021 CKD-EPI cystatin C equation (PMID 34554658) gives a more accurate GFR in muscular individuals and in lifters on creatine.

If your creatinine-based eGFR looks borderline but your cystatin C-based eGFR is normal and your UACR is normal, your kidneys are not damaged. Your lab value just caught up with your gym habits.

High-dose vitamin C can also falsely elevate creatinine on some assays through chemical interference. This is another reason UACR and cystatin C matter for confirmation.

What You Can Do

1. Get eGFR and UACR measured. If you are over 40, or have any risk factor, ask at your next physical. If your doctor only orders creatinine, ask for UACR explicitly. Cost: under $50 in most systems.
2. Know your blood pressure. Buy a home cuff (~$50). Measure twice a week. Target <130/80 for most adults. If you consistently run above, talk to your doctor.
3. Know your HbA1c. Every adult over 40, every 1-3 years. If borderline or high, address it.
4. Stop chronic NSAID use. Acute pain is fine. Daily ibuprofen for months is not. Switch to acetaminophen or non-drug options for ongoing issues.
5. Drink water, not soda. Sugar-sweetened beverages drive weight, insulin resistance, and hyperfiltration. Water is free.
6. Don't smoke. Moderate alcohol. The two biggest modifiable amplifiers after BP and glucose.
7. If you lift or take creatine, request cystatin C-based eGFR. Don't let a creatinine artifact get you labeled with "kidney damage" you don't have.

Frequently Asked Questions

Q: I feel completely fine. Do I really need kidney tests? A: Yes, if you are over 40 or have any risk factor (diabetes, hypertension, family history, obesity, smoking, NSAID use, African ancestry). Early CKD has no symptoms. The entire point of screening is to catch it before it announces itself.

Q: My eGFR is 58. Am I doomed? A: No. eGFR 58 is stage G3a, which is common in adults over 60 and often stable for decades with good BP and glucose control. What matters is the trajectory (is it declining fast?), the UACR (is there protein leak?), and the underlying drivers (is diabetes or hypertension uncontrolled?). Many people with stage 3a never progress.

Q: Does drinking extra water "flush" the kidneys and help? A: Adequate hydration prevents concentration and reduces some forms of injury. But there is no evidence that forcing extra water beyond thirst improves kidney function in healthy people. In established CKD, excess water can actually be harmful. The target is pale yellow urine, not maximum volume.

Q: Are SGLT2 inhibitors worth asking about even if I'm not diabetic? A: If you have CKD (eGFR <60 or UACR >200), the DAPA-CKD and EMPA-KIDNEY trials (PMIDs 32970396 and 36331190) showed benefit regardless of diabetes status. SGLT2 inhibitors are now guideline-recommended for non-diabetic CKD with significant proteinuria. Ask a nephrologist.

Q: I take creatine. Should I stop? A: No, if your only reason is a slightly elevated creatinine on a routine panel. Creatine raises creatinine without damaging nephrons (PMIDs 28615996, 10449017). Request cystatin C-based eGFR and UACR — if those are normal, your kidneys are fine.

Q: Is a high-protein diet hurting my kidneys? A: Not if your kidneys are healthy. The 2018 Devries meta-analysis (PMID 30383278) found no effect on kidney function in healthy adults. Protein restriction is only indicated once CKD is diagnosed, and even then the benefits are modest.

The Bottom Line

Chronic kidney disease is the quietest deadly epidemic in aging medicine. It has:

• A prevalence larger than diabetes
• A mortality trajectory climbing toward the top five causes of lost life years
• No symptoms in early stages
• Two cheap tests that catch nearly all of it
• Four dominant drivers, all of which are modifiable or measurable
• Three drug classes (SGLT2, GLP-1, finerenone) that finally move outcomes after two decades of stagnation

The two-number dashboard is eGFR and UACR. Know both. Update them annually if you are over 40 or carry any risk factor. If they are normal, your job is to keep your blood pressure, blood sugar, and habits inside the range that keeps them normal. If they are abnormal, your job is to get into the care of a doctor who knows the current evidence, because the tools to slow CKD in 2026 are meaningfully better than they were in 2019.

Nine out of ten people with CKD don't know they have it. The solution is not fear. It is two lab tests and a blood pressure cuff.

Get the numbers. Know the numbers. Act on the numbers.

Your kidneys won't tell you themselves.